Eosinophilic asthma is characterized by high eosinophil levels in induced sputum and peripheral blood. Elevated airway eosinophil counts can be detected in more than 50% of asthmatics and associated with more symptoms, frequent exacerbations, and greater airflow limitation. Increased blood eosinophils (BEs) also predict a greater response to new biological therapies (mepolizumab, reslizumab). Higher pretreatment BE levels are also related to a better response to omalizumab,3 which reduces BE, fractional exhaled nitric oxide (FENO), serum periostin, and exacerbations. Therefore, a higher effect on eosinophil count reduction may lead to greater clinical improvements. Accordingly, if omalizumab response is eosinophilic dependent, it might be reduced in subjects with persistent high BE counts after anti-IgE therapy.
Higher blood eosinophil levels after omalizumab treatment are associated with poorer asthma outcomes / Sposato, Bruno; Scalese, Marco; Milanese, Manlio; Masieri, Simonetta; Cavaliere, Carlo; Latorre, Manuela; Scichilone, Nicola; Ricci, Alberto; Cresti, Alberto; Santus, Pierachille; Olivieri, Carmela; PERRELLA, ANTONIO; Rogliani, Paola; Paggiaro, Pierluigi. - In: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. IN PRACTICE. - ISSN 2213-2198. - Epub 2019 Mar 19:(2019). [10.1016/j.jaip.2019.03.006]
Higher blood eosinophil levels after omalizumab treatment are associated with poorer asthma outcomes
Masieri, Simonetta;Cavaliere, Carlo;Ricci, Alberto;PERRELLA, ANTONIO;
2019
Abstract
Eosinophilic asthma is characterized by high eosinophil levels in induced sputum and peripheral blood. Elevated airway eosinophil counts can be detected in more than 50% of asthmatics and associated with more symptoms, frequent exacerbations, and greater airflow limitation. Increased blood eosinophils (BEs) also predict a greater response to new biological therapies (mepolizumab, reslizumab). Higher pretreatment BE levels are also related to a better response to omalizumab,3 which reduces BE, fractional exhaled nitric oxide (FENO), serum periostin, and exacerbations. Therefore, a higher effect on eosinophil count reduction may lead to greater clinical improvements. Accordingly, if omalizumab response is eosinophilic dependent, it might be reduced in subjects with persistent high BE counts after anti-IgE therapy.File | Dimensione | Formato | |
---|---|---|---|
Sposato_Higher_2019.pdf
solo gestori archivio
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
350.67 kB
Formato
Adobe PDF
|
350.67 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.